logo
On Raises 2025 Guidance After Reporting Record Sales in Q1

On Raises 2025 Guidance After Reporting Record Sales in Q1

Yahoo13-05-2025

Shares for On Holding AG were up nearly 8 percent on Tuesday morning after the Swiss athletic company said it reached record quarterly net sales in its most recent earnings report.
The company also raised its guidance, which is in contrast to many footwear firms that have scrapped guidance altogether amid uncertainty over tariffs and the global economy.
More from WWD
Under Armour Continues to Struggle, But Makes Progress on Restructuring Plan
Coty Reports $71.1M Loss on Skkn Divestiture Amid Q3 Revenue Decline
The Estée Lauder Cos. Forecasts 9 Percent Drop in Sales in 2025, but Expects Return to Growth Next Year
In the first quarter of fiscal 2025, On saw net sales increase 43 percent to 726.6 million Swiss francs, compared to 508.2 million Swiss francs in Q1 2024. Net income, however, decreased by 38.0 percent in Q1 to 56.7 million Swiss francs from 91.4 million Swiss francs the same time last year.
The company said that the performance this quarter was ahead of expectations and was driven by On's multi-channel strategy, including continued momentum in the direct-to-consumer channel and strong demand from wholesale partners.
On noted that DTC net sales increased by 45.3 percent to 276.9 million Swiss francs, while net sales through the wholesale sales channel increased by 41.5 percent to 449.7 million Swiss francs.
By region, On said that net sales in Europe, Middle East and Africa grew 33.6 percent to 168.6 million Swiss francs, in the Americas increased 32.7 percent to 437.4 million Swiss francs, and in Asia-Pacific it jumped 130.1 percent to 120.6 million Swiss francs.
And by category, net sales from shoes increased 40.5 percent to 680.9 million Swiss francs, apparel was up 93.1 percent to 38.1 million Swiss francs, and accessories jumped 99.2 percent to 7.6 million Swiss francs in the first quarter.
Caspar Coppetti, co-founder and executive co-chairman of On, said in a statement that the company's Q1 results 'reflect the strong momentum of our brand across all channels, regions and product categories.'
'Looking into the second quarter and beyond, we are energized by the global traction and cultural resonance of On as a head-to-toe sportswear brand,' Coppetti said. 'As we solidify our premium positioning in the marketplace, we will continue to focus on what differentiates us — combining performance and design with a constant thirst for innovations big and small.'
Martin Hoffmann, co-chief executive officer and chief financial officer of On, added that Q1 sales were 'further elevated' by product launches like the Cloud 6 and the Cloudsurfer 2.
'We are thrilled to see that the continued growing strength of our DTC channel as well as improved operational execution across our supply chain have further contributed to a significant profitability expansion,' Hoffmann said.
Following a strong start to the year, the company is raising its full-year 2025 net sales guidance and now expects to reach at least 28 percent growth on a constant currency basis, equivalent to 2.86 billion Swiss francs at current spot rates. The company added that it now expects a gross profit margin in the range of 60.0 percent and 60.5 percent for the full year, and an adjusted EBITDA margin in the range of 16.5 percent and 17.5 percent.
The company further noted that its guidance includes the additional U.S. tariffs in place during the current 90-day pause on the country-specific reciprocal tariffs.
'As we look ahead, we are confident that our commitment to bold innovation, operational excellence, and elevated consumer experiences will drive market share gains and further cement On's global premium position, allowing us to navigate the higher levels of planning uncertainty in today's market environment,' Hoffmann added.
Best of WWD
Mikey Madison's Elegant Red Carpet Shoe Style [PHOTOS]
Julia Fox's Sleekest and Boldest Shoe Looks Over the Years [Photos]
Crocs Collaborations From Celebrities & Big Brands You Should Know

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway
Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway

Yahoo

time2 hours ago

  • Yahoo

Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway

Guidance confirmed for clinical milestones for MP0533 and MP0712 in H2 2025 Cash reach now anticipated to extend into 2028 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ('Molecular Partners' or the 'Company'), today announces that it has performed a strategic review of its current operations and headcount, with the objectives of increased efficiency in the organization and to sharpen the focus on advancing its clinical assets. As a result of this review the Company has informed the Amt für Wirtschaft of Kanton Zürich (Office for Economic Affairs) of its intention to reduce its current workforce by no more than 40 positions, representing a potential of ~24% of all positions. "With strong data emerging from MP0533 and MP0712, our priority is to develop these assets which can provide most value for patients and shareholders. The plan to right-size the organization extends our cash reach into 2028, supporting both the development of our clinical assets and advancement of new products into the pipeline. We recognize the contribution that all of our talented employees have made to Molecular Partners and thank them as we take this difficult decision. The Board and I believe this is the right strategic path for the company to help secure its future success," said Patrick Amstutz, CEO of Molecular Partners. In accordance with Swiss employment law a consultation process with employees has been initiated. Upon completion of the consultation process, the Company will offer affected employees support. This will include, but will not be limited to, severance packages, and support in seeking new employment, coaching or training opportunities. Molecular Partners foresees the full implementation of these changes enacted by the end of 2025 and the reduction of costs to become fully effective early in 2026. As a result of these headcount reductions, the company now anticipates its cash runway to extend into 2028, beyond its prior guidance of 2027. The strategic review was undertaken to identify certain redundancies within the organization, with a focus on research and associated functions. The company will report its half-year financials on August 25, 2025. Molecular Partners maintains its previously announced timelines with clinical data from both MP0533 and MP0712 expected in H2 2025. About Molecular Partners AG Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics for medical challenges other drug modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit and find us on LinkedIn and Twitter / X @MolecularPrtnrs For further details, please contact:Seth Lewis, SVP Investor Relations & StrategyConcord, Massachusetts, +1 781 420 2361 Laura Jeanbart, PhD, Head of Portfolio Management & Communications Zurich-Schlieren, Tel: +41 44 575 19 35 Cautionary Note Regarding Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners' current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners' product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners' collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; and Molecular Partners' expected business and financial outlook, including anticipated expenses and cash utilization for 2025 and its expectation of its current cash runway and the expected use of proceeds from the October 2024 offering. These statements may be identified by words such as 'aim', "anticipate', 'expect', 'guidance', 'intend', 'outlook', 'plan', 'potential', 'will' and similar expressions, and are based on Molecular Partners' current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners' expectations include its plans to develop and potentially commercialize its product candidates; Molecular Partners' reliance on third party partners and collaborators over which it may not always have full control; Molecular Partners' ongoing and planned clinical trials and preclinical studies for its product candidates, including the timing of such trials and studies; the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with future clinical trials; the timing of and Molecular Partners' ability to obtain and maintain regulatory approvals for its product candidates; the extent of clinical trials potentially required for Molecular Partners' product candidates; the clinical utility and ability to achieve market acceptance of Molecular Partners' product candidates; the potential that Molecular Partners' product candidates may exhibit serious adverse, undesirable or unacceptable side effects; the impact of any health pandemic, macroeconomic factors and other global events on Molecular Partners' preclinical studies, clinical trials or operations, or the operations of third parties on which it relies; Molecular Partners' plans and development of any new indications for its product candidates; Molecular Partners' commercialization, marketing and manufacturing capabilities and strategy; Molecular Partners' intellectual property position; Molecular Partners' ability to identify and in-license additional product candidates; unanticipated factors in addition to the foregoing that may cause Molecular Partners' actual results to differ from its financial and business projections and guidance; and other risks and uncertainties set forth in Molecular Partners' Annual Report on Form 20-F for the year ended December 31, 2024 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners' website at In addition, this press release contains information relating to interim data as of the relevant data cutoff date, results of which may differ from topline results that may be obtained in the future. Any forward-looking statements speak only as of the date of this press release and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease
AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease

Yahoo

time3 hours ago

  • Yahoo

AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease

Seongnam-si, South Korea and Abu Dhabi, UAE, June 09, 2025 (GLOBE NEWSWIRE) -- AriBio Co., Ltd. ("AriBio"), a South Korean biopharmaceutical company specializing in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi (collectively 'Arcera'), today announced the signing of exclusive licensing and commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer's disease. Under the terms of the agreements, Arcera will have exclusive rights to commercialize AR1001 in its key markets, including Latin America, the Middle East, Southern Africa, Ukraine and select Eurasian countries. AriBio will be responsible for manufacturing and supplying the product. The total deal value is estimated at USD 600 million across the development, launch and commercialization period, contingent upon the achievement of certain milestones. AR1001 is a novel, disease-modifying, once-daily oral phosphodiesterase-5 (PDE5) inhibitor currently being studied in a global Phase 3 clinical trial (POLARIS-AD) for the treatment of early-stage Alzheimer's disease. The enrollment target for the Phase 3 trial has been reached, and the topline results are expected in the first half of 2026. Facilitated by the Korea Development Bank (KDB) and aligned with the Korean government's policy to foster the biohealth industry, this collaboration represents a significant step forward to enhance the global competitiveness of Korea's pharmaceutical and biotech industry. "This partnership with Arcera marks a significant milestone in our mission to bring innovative treatments to patients worldwide," said Jai Jun Choung, CEO of AriBio. "Arcera's strong commercial capabilities and deep understanding of the high-growth markets make them an ideal partner to advance AR1001 in these important regions." "We are excited to enter into this collaboration with AriBio, which will provide access to AR1001, a novel treatment, for patients across these countries," said Isabel Afonso, CEO of Arcera. "This agreement aligns with our strategy to expand our neuroscience portfolio and reinforces our commitment to providing access to novel therapies in regions with significant unmet medical needs." The agreement underscores both companies' dedication to addressing unmet medical needs in neurodegenerative diseases and enhancing patient access to innovative therapies globally. This deal follows the Memorandum of Understanding signed between AriBio and Arcera in March 2025, where both parties agreed to strengthen their partnership by actively exploring strategic investments, and advancing joint research and development based on shared interests. ENDS About AriBio Co., Ltd. Founded in 2010, AriBio is a clinical-stage biopharmaceutical company headquartered in South Korea, with offices located in the United States to manage global clinical operations and regulatory affairs. The company focuses on the development of novel therapies for neurodegenerative diseases, including Alzheimer's disease. AriBio continues to expand its partnerships to accelerate the development and delivery of life-changing treatments to patients worldwide. About Arcera Arcera is a global life sciences company, headquartered in Abu Dhabi. Arcera develops, manufactures, and commercializes a broad range of high-quality proven and innovative medicines in key international markets. Its portfolio exceeds 2,000 medicines covering wide therapeutic areas which reach patients in ninety countries in four continents, backed by manufacturing and packing sites across the world. Arcera was established by the sovereign wealth fund, ADQ to realize Abu Dhabi's ambition as a global leader in innovative and sustainable healthcare. To learn more about Arcera, visit Attachment AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease CONTACT: Tanya Xi, MD, PhD, MBA, Senior Director, Business Development & Medical Affairs, AriBio (US) AriBio Co., Ltd. tanyaxi@ Rafael Ferrer, SVP Corporate Development. Arcera rferrer@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

UBS Capital Requirements Rise Following Switzerland's Proposal
UBS Capital Requirements Rise Following Switzerland's Proposal

Yahoo

time3 hours ago

  • Yahoo

UBS Capital Requirements Rise Following Switzerland's Proposal

Switzerland's Federal Department of Finance ('FDF') has proposed stricter rules for UBS Group AG UBS following its takeover of Credit Suisse. The move has been attempted to reduce the risks of another Credit Suisse-style Swiss government has proposed that UBS should fully capitalize its foreign subsidiaries, up from the current 60% threshold. This will require UBS to increase its common equity tier-one capital by up to $26 bank will be allowed to reduce its Additional Tier 1 (AT1) bond holdings by $8 billion. Still, this will result in a net increase of $18 billion in FDF stated, 'The Credit Suisse crisis made it clear that the Swiss parent bank's capital base was insufficient. The implementation of the package of measures is intended to substantially reduce the likelihood that another systemically important bank in Switzerland will get into a severe crisis, and that emergency measures by the state will be required.'Per the FDF, this estimate assumed no change in UBS's balance sheet size, risk-weighted assets or its potential use of mitigation said it 'strongly disagrees with the extreme increase in capital requirements that has been proposed. These changes would result in capital requirements that are neither proportionate nor internationally aligned.'Notably, the 'too big to fail' proposals (still subject to parliamentary approval) have come after the Swiss financial regulator granted capital relief to Credit Suisse in 2017, allowing the bank to inflate the value of its foreign the new capital proposals will be put out for consultation before being submitted to the the FDF, the proposed reforms will not become law before 2028, and UBS will be given a six to eight-year transition period to implement the changes once the legislation comes into force. UBS took over its rival Credit Suisse in a state-sponsored rescue in then, UBS has been facing challenges and legal claims, which is increasing costs. Last month, UBS agreed to pay $511 million to resolve a tax probe by the U.S. Department of Justice against Credit Suisse for preparing false income tax returns and tax UBS is on track to substantially complete the integration of Credit Suisse by the end of 2026 and, hence, achieve the targeted cost the first quarter of 2025, UBS completed consolidating its branch network in Switzerland, merging 95 branches since the July 2024 merger with Credit Suisse. The company is initiating its Swiss business migrations and aims to complete the migrations by the first quarter of the first quarter of 2025, UBS realized an additional $0.9 billion in gross cost savings. Cumulative gross cost savings at the end of the first quarter of 2025 amounted to $8.4 billion compared with the 2022 combined cost base of UBS and Credit Suisse. This represents around 65% of its ambition to deliver $13 billion in annualized exit rate gross cost savings by the end of 2026. Over the past six months, UBS shares have gained 6.1% compared with the industry's growth of 23.1%. Image Source: Zacks Investment Research Currently, UBS carries a Zacks Rank #3 (Hold). A couple of better-ranked peer stocks are Deutsche Bank Aktiengesellschaft DB and Mitsubishi UFJ Financial Group, Inc. MUFG, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks estimates for DB for the current year have been revised 4.2% upward over the past 60 days. Over the past six months, DB shares have soared 57.7%.MUFG's current fiscal-year earnings estimates have been revised 4.6% higher over the past 60 days. MUFG shares have gained 16.5% over the past six months. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Deutsche Bank Aktiengesellschaft (DB) : Free Stock Analysis Report UBS Group AG (UBS) : Free Stock Analysis Report Mitsubishi UFJ Financial Group, Inc. (MUFG) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store